Helix Biopharma Corp (HBPCF) 1.3902 $HBPCF Helix

New Post Public Reply Private Reply Replies (0) Message Board

Aug 5, 2016 at 5:02 PM

Helix Biopharma Corp (HBPCF) 1.3902 $HBPCF

Helix BioPharma Corp. Closes CAD1.8 Million Private Placement
Marketwired - Fri Jul 29, 3:01PM CDT
AURORA, ON--(Marketwired - Jul 29, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for aggregate gross proceeds of approximately CAD1.8 million.
HBP: 6.02 (+0.24), HBP.TO: 1.96 (-0.04)

Helix BioPharma Corp. Announces Agreement in Principle With National Research Council of Canada to Collaborate on Various Immuno-Oncology Initiatives
Marketwired - Mon Jul 18, 3:10PM CDT
AURORA, ON--(Marketwired - Jul 18, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced that an Agreement in Principle ("Agreement"

has been reached with the National Research Council of Canada ("NRC"

to collaborate on various immuno-oncology initiatives.
HBP: 6.02 (+0.24), HBP.TO: 1.96 (-0.04)

Helix BioPharma Corp. Appoints Evolution Life Science Partners as Advisors
Marketwired - Thu Jun 02, 7:00AM CDT
AURORA, ON--(Marketwired - Jun 2, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, a clinical stage biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the appointment of Evolution Life Science Partners to act as advisors to the Company. Activities the Company may pursue could include, but are not limited to, partnering or other collaboration agreements. The Company does not intend to disclose developments with respect to this process except as required under applicable securities regulations.
HBP: 6.02 (+0.24), HBP.TO: 1.96 (-0.04)

First Patient Dosed in Phase II Study of L-DOS47 in Non-Small Cell Lung Cancer
Marketwire Canada - Wed May 11, 6:30AM CDT
AURORA, ON--(Marketwired - May 11, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, a clinical stage biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the first patient was dosed in the Phase II component of study LDOS002.
HBP: 6.02 (+0.24), HBP.TO: 1.96 (-0.04)

Helix BioPharma Corp. Subsidiary, Helix Polska Sp zo.o., Qualifies for CAD4.1 Million Grant From the Polish National Center for Research and Development
Marketwire Canada - Mon May 09, 6:30AM CDT
AURORA, ON--(Marketwired - May 9, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, a clinical stage biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that its wholly owned subsidiary, Helix Polska Sp. z o.o. qualifies for a grant of approximately PLN12.5mil from the Polish National Centre for Research and Development to develop V-DOS47 in breast cancer. The acceptance of the grant is subject to review and approval of the final terms and conditions by Helix's management and Board of Directors and may be subject to conditions imposed by the granting authority and corporate or other approvals.
HBP: 6.02 (+0.24), HBP.TO: 1.96 (-0.04)

Helix BioPharma Corp. Closes CAD4.7 Million Private Placement Financing
Marketwired - Fri Apr 29, 6:30AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for aggregate gross proceeds of approximately CAD4.7 million.
HBP: 6.02 (+0.24), HBP.TO: 1.96 (-0.04)

First Patient Enrolled in Phase II Study of L-DOS47 in Non-Small Cell Lung Cancer
Marketwire Canada - Thu Apr 28, 6:30AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, a clinical stage biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the first patient has been enrolled in the Phase II component of study LDOS002.
HBP: 6.02 (+0.24), HBP.TO: 1.96 (-0.04)

Trial Steering Committee Recommends Initiation of Phase II L-DOS47 Study in Non-Small Cell Lung Cancer
Marketwire Canada - Thu Apr 21, 4:00AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, a clinical stage biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the recommendation by the Trial Steering Committee to initiate the Phase II component of the LDOS002 study.
HBP: 6.02 (+0.24), HBP.TO: 1.96 (-0.04)

Helix BioPharma Corp. Announces Important Additions to Its Leadership Team
Marketwire Canada - Wed Apr 20, 6:30PM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the appointment of Dr. Patrick Frankham to Chief Operating Officer and the promotion of Mr. Steve Demas to the position of Chief Medical Officer. Dr. Frankham and Mr. Demas will both report directly to Dr. Sven Rohmann, Helix's newly appointed Chief Executive Officer.
HBP: 6.02 (+0.24), HBP.TO: 1.96 (-0.04)

Helix Biopharma Corp. Announces the Receipt of Subscription Agreements Totalling CAD4.7 Million for Private Placement Financing
Marketwire Canada - Fri Apr 15, 6:00AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has received private placement subscription agreements for units for aggregate gross proceeds of approximately CAD4.7 million.
HBP: 6.02 (+0.24), HBP.TO: 1.96 (-0.04)

Helix BioPharma Corp. Announces CEO Change
Marketwire Canada - Tue Mar 29, 3:46PM CDT
Helix BioPharma Corp. (hereinafter defined as "Helix" or the "Company"

(TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, announces that Dr. Zbigniew Markowski will be stepping down, for personal and family reasons, from his positions as Chief Executive Officer of Helix BioPharma Corp and Chairman of Helix Polska, effective March 29th, 2016. Stepping into both roles, effective immediately, will be Dr. Sven Rohmann.
HBP: 6.02 (+0.24), HBP.TO: 1.96 (-0.04)

Helix Biopharma Corp. Announces Second Quarter Fiscal 2016 Results
Marketwire Canada - Wed Mar 16, 3:15PM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the second quarter of fiscal 2016, ended January 31, 2016.
HBP: 6.02 (+0.24), HBP.TO: 1.96 (-0.04)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Comparent Unveils Key Insights with Top 100 List

The Ebb and Flow of Vacation Rental Giants Ever noticed how some industries just sneak up and suddenly transform landscapes? Vacation rental management is one of those sneaky offenders. At the forefront of keeping tabs on this bustling sector, Comparent just dropped a meaty second annual roster—the Comparent 100—showcasing the biggest players flexing their muscles in...

Varda Space's Dual Launch Signals Orbital Ambitions

It's not every day you see two commercial rockets heading to orbit on the same ride, but that's precisely what Varda Space Industries just pulled off. With the W-8 and W-9 vehicles blasting off together, Varda is positioning itself for a leap in orbital operations. They've hitched a ride aboard SpaceX's Transporter-18 mission, and this is more than just a double...

Li-Fire Expands Fire Safety Amid Rising Battery Risks

A Crunchy Look at New Fire Safety Moves Well, folks, here's a twist we didn't see coming but sure makes sense in today's electrifying business landscape. Li-Fire, the big brains behind lithium battery fire suppression, is spreading its wings nationwide, or at least its wholesale and distribution programs are. And right ahead of National Fire Safety Week no less—talk...

Athlete Threats: Public Info Fuels Security Risks

Public Exposure: The New Athlete Achilles' Heel Imagine sitting on millions while living in a glass house. That's the kind of predicament today's athletes find themselves in, thanks to the treasure trove of public information spilling their personal lives all over the internet. According to the latest Hush Intelligence Athlete Threat Report 2026, this very exposure has...

SaponiQ Reinvents Body Care with Botanical Soap Bars

Breaking Through with Simple Innovation I'll be the first to say it's not every day you hear about a soap company trying to shake things up in body care like it’s a tech startup, but here’s SaponiQ taking a wild swing at it with their lineup of botanical cleansing bars. These things are whipped up in their own U.S.-based facility using some fancy cold-process...

Neutonic Sets Sights on U.S. with Walmart Expansion

Neutonic Embarks on Major Expansion with Walmart Well, here we go. Neutonic is stepping up to the big leagues by planting its flag in nearly 1,000 Walmart stores across the U.S. This move lands them right in the thrumming heart of Walmart's new Mood & Mind beverage set. It's about time this brand brings its functional beverages to American shoppers already drained by...

Rochester Memorial Installations: Key Timelines Revealed

There are times in life where patience isn’t just a virtue, it’s a necessity—memorial installations are one of those instances. In Rochester, NY, folks dealing with the loss of a loved one want more than just closures; they want to commemorate their people in a way that lasts. But how long does it take, really, to set these tributes in stone? Understanding the...

Gateway Unveils All-In-One Award Travel Platform

Transforming Loyalty with point.me's Gateway Here's the deal: the loyalty program game just changed. Point.me rolled out this slick beast called Gateway, and it's weaving award travel booking right into your everyday banking apps. That's right, ditch those clunky third-party sites, because now you can browse, compare, transfer, and book your award travel directly from...

Nelson-Jameson Boosts Cold Storage in California Move

An Icy Boost for the West Coast Dairy Player Every now and then, a company gets its cold storage game just right. Nelson-Jameson has added fresh muscle to its Turlock facility in California, making waves with serious logistical upgrades. The company's dogged pursuit of better operational efficiency in dairy processing isn't just about bragging rights. It's plain old good...

Fresh Leadership at Master Group: Langelier Steps In

Changing of the Guard: A Calculated Move It's not every day you see a company make a move as calculated and thoughtful as the one the Master Group just pulled. Rémy Langelier is set to transition into the shoes of CEO by early 2027, fresh off the heels of Louis St-Laurent. This isn't just any executive shuffle, folks—it's a strategic baton pass spawning an investment...